On this episode of Stock Movers:
- Palantir Technologies (PLTR) shares fall, taking a breather after rallying more than 170% this year. The data-analysis software company raised its full-year forecast and reported third-quarter results that beat expectations. While analysts are broadly positive on the report, they flag concerns over the stock’s premium valuation.
- Novo Nordisk (NVO) confirms it has submitted an updated proposal to buy Metsera and says it believes the bid “complies with all applicable laws.”
- Spotify Technology (SPOT) reported active users and revenue in the third quarter that surpassed analysts’ expectations, easing concerns about co-founder and Chief Executive Officer Daniel Ek stepping down at the end of the year. Monthly active users climbed 11% from a year earlier to 713 million, exceeding analysts’ estimates of 710.6 million. The Stockholm-based company said revenue gained 7% to €4.27 billion ($4.9 billion), also beating expectations. Premium subscribers were roughly in line with projections.

On this episode of Stock Movers: - Palantir Technologies (PLTR) shares fall, taking a breather after rallying more than 170% this year. The data-analysis software company raised its full-year forecast and reported third-quarter results that beat expectations. While analysts are broadly positive on the report, they flag concerns over the stock&rsquo;s premium valuation. - Novo Nordisk (NVO) confirms it has submitted an updated proposal to buy Metsera and says it believes the bid &ldquo;complies with all applicable laws.&rdquo; - Spotify Technology (SPOT) reported active users and revenue in the third quarter that surpassed analysts&rsquo; expectations, easing concerns about co-founder and Chief Executive Officer Daniel Ek stepping down at the end of the year. Monthly active users climbed 11% from a year earlier to 713 million, exceeding analysts&rsquo; estimates of 710.6 million. The Stockholm-based company said revenue gained 7% to &euro;4.27 billion ($4.9 billion), also beating expectations. Premium subscribers were roughly in line with projections.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Palantir Slides, Novo Boosts Bid, Spotify Beats on Users

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/dfc5eaa7-011c-4501-822d-b38b010d5e61/transcript

On This episode of Stock Movers:
- BP agreed to sell a majority stake in its Castrol lubricants division to US investment firm Stonepeak Partners to raise about $6 billion.
- French biotech company Abivax started the year with a market value of less than $500 million. After a meteoric rally, it’s now worth more than $8 billion — and some analysts see the potential for even more gains
- B&M's stock has fallen 56% in 2025, extending the previous year’s 34% drop, as the firm struggles to contend with a cocktail of rising competition, increasing wage costs and a pinch on the low-income households that have been key to its past success.

On This episode of Stock Movers: - BP agreed to sell a majority stake in its Castrol lubricants division to US investment firm Stonepeak Partners to raise about $6 billion. - French biotech company Abivax started the year with a market value of less than $500 million. After a meteoric rally, it&rsquo;s now worth more than $8 billion &mdash; and some analysts see the potential for even more gains - B&amp;M's stock has fallen 56% in 2025, extending the previous year&rsquo;s 34% drop, as the firm struggles to contend with a cocktail of rising competition, increasing wage costs and a pinch on the low-income households that have been key to its past success.

BP Spin Off, Abivax's 1600% Gains, B&M's Woes

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/35e87da0-4b06-4474-bc50-b3bd00a8afca/transcript

On This episode of Stock Movers:
- BP Plc agreed to sell a majority stake in its Castrol lubricants division to US investment firm Stonepeak Partners to raise about $6 billion.
- Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as the French drugmaker tries to expand a vaccines business currently anchored by its flu shot franchise.
- Fresnillo and other european mining stocks may be active on Wednesday as gold rises above $4,500 an ounce for the first time on escalating tensions in Venezuela and expectations for more US interest rate cuts. Silver, platinum and copper also hit records

On This episode of Stock Movers: - BP Plc agreed to sell a majority stake in its Castrol lubricants division to US investment firm Stonepeak Partners to raise about $6 billion. - Sanofi agreed to buy Dynavax Technologies Corp. for about $2.2 billion, as the French drugmaker tries to expand a vaccines business currently anchored by its flu shot franchise. - Fresnillo and other european mining stocks may be active on Wednesday as gold rises above $4,500 an ounce for the first time on escalating tensions in Venezuela and expectations for more US interest rate cuts. Silver, platinum and copper also hit records

BP Spin Off, Sanofi Down, Fresnillo Up

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/677f5eea-741f-4214-a4d0-b3bd009559bc/transcript

On this episode of Stock Movers:
- Novo Nordisk (NVO) shares rallied in trading today following the drugmaker getting US approval to sell a pill version of its blockbuster obesity shot Wegovy. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. The pill is crucial for Novo’s strategy to take on Eli Lilly, which has said its own oral obesity drug could be approved by March. That would give Novo a head start of just a few months. 
- ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. The Santa Clara, California-based enterprise tech company will pay in cash for San Francisco-based Armis, according to a statement Tuesday that confirmed an earlier Bloomberg News report. ServiceNow, which provides software that helps companies organize and automate their personnel and information technology operations, has become a dominant platform for enterprise workflow. In March, ServiceNow struck an agreement to buy the artificial intelligence firm Moveworks Inc. for $2.85 billion as part of its push into AI tools that can complete tasks without human supervision. Shares of the startup fell during trading on Tuesday.
- Sable (SOC) shares rose as much as 30% after the company said that the US Department of Transportation, Pipeline and Hazardous Materials Safety Administration approved the firm’s Las Flores pipeline restart plan.

On this episode of Stock Movers: - Novo Nordisk (NVO) shares rallied in trading today following the drugmaker getting US approval to sell a pill version of its blockbuster obesity shot Wegovy. Novo will start selling the pill in the US in early January, the company said in a statement Monday. It is approved to help people lose weight or maintain previous weight loss over the long term. The pill is crucial for Novo&rsquo;s strategy to take on Eli Lilly, which has said its own oral obesity drug could be approved by March. That would give Novo a head start of just a few months. - ServiceNow (NOW) has reached a deal to buy the cybersecurity startup Armis in a deal valued at $7.75 billion, representing its largest acquisition to date. The Santa Clara, California-based enterprise tech company will pay in cash for San Francisco-based Armis, according to a statement Tuesday that confirmed an earlier Bloomberg News report. ServiceNow, which provides software that helps companies organize and automate their personnel and information technology operations, has become a dominant platform for enterprise workflow. In March, ServiceNow struck an agreement to buy the artificial intelligence firm Moveworks Inc. for $2.85 billion as part of its push into AI tools that can complete tasks without human supervision. Shares of the startup fell during trading on Tuesday. - Sable (SOC) shares rose as much as 30% after the company said that the US Department of Transportation, Pipeline and Hazardous Materials Safety Administration approved the firm&rsquo;s Las Flores pipeline restart plan.

Novo Nordisk Rallies, ServiceNow Dips, Sable Rises

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/8e2b4a94-214c-4021-8e16-b3bc016cf117/transcript

Palantir Slides, Novo Boosts Bid, Spotify Beats on Users

In 1 playlist(s)

Stock Movers

Social links

Follow podcast

Recent clips